UPDATE 1-Novartis cuts outlook, Q2 profit up 18 pct

(Reuters) - Novartis said it now expected mid-single-digit growth in
group net sales and low-single-digit growth in drug sales,
slightly lower than its previous outlook.




Net profit at Novartis from continuing operations rose 18
percent to $1.94 billion in the second quarter due to strong
sales of top-selling drugs Diovan and Glivec and in line with
analysts' forecasts.


Read more at Reuters.com Mergers News

Choking risk for babies prompts Gerber recall

(Reuters) - The packages were distributed in the United States, Puerto
Rico and the Caribbean, the company said on its Web site.




Novartis said the recall was minor and that it would have no
financial impact on the group, nor would the group make
provisions to cover any losses from the recall.


Read more at Reuters.com Mergers News